Stay updated with breaking news from Cb 011. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The FDA has granted a fast track designation to CB-011, a CRISPR-edited allogeneic CAR T-cell therapy developed by Caribou Biosciences, for the treatment of patients with relapsed/refractory multiple myeloma.
Caribou Biosciences, Inc. (CRBU) announced the FDA has granted Fast Track designation to CB-011, which is being developed for relapsed or refractory multiple myeloma.
Pasien yang sudah keluar sebanyak 125.196 orang. Pasien yang keluar terdiri dari rujuk ke rumah sakit lain 1.011 orang, sembuh 123.591 orang dan meninggal 594 orang.